Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved a new drug application labeling supplement that allows readministration of iDose TR with a repeat treatment protocol, according to a press release from Glaukos.
With the updated labeling, iDose TR (travoprost intracameral implant) may be readministered more than once in patients with corneal endothelial cell density parameters that demonstrate a healthy cornea.
The decision is supported by positive data from the iDose TR exchange trial, which showed the safety and tolerability of a second